Polio vaccine is under clinical development by Beijing Tiantan Biological Products and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Polio vaccine’s likelihood of approval (LoA) and phase transition for Poliomyelitis took place on 03 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Polio vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Polio vaccine overview

Poliomyelitis vaccine is under development for the prevention of poliomyelitis. The drug candidate is produced from wild-type polio virus strains of each serotype that have been inactivated (killed) with formalin. The weakened agents stimulate the body's immune system. It is administered through intramuscular route.

Beijing Tiantan Biological Products overview

Beijing Tiantan Biological Products (Tiantan Biological), a subsidiary of China National Pharmaceutical Group Corp, develops and manufactures plasma protein products and viral vaccines. Its blood products include Guizhou blood injection, blood human albumin, rongsheng human albumin, rongsheng human immunoglobulin and rongsheng freeze-dried hepatitis B human immunoglobulin. The company also provides consulting services for scientific researchers in the field of hematology. Tiantan Biological operates single plasma collection bases in provinces and autonomous regions across China. The company markets its products in China and abroad. Tiantan Biological is headquartered in Beijing, China

Quick View Polio vaccine LOA Data

Report Segments
  • Innovator
Drug Name
  • Polio vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.